Verastem, Inc. posted an updated corporate presentation on May 7, 2026, detailing its approved AVMAPKI FAKZYNJA CO-PACK for KRAS mt recurrent LGSOC and clinical pipeline milestones.
Key takeaways
Posted updated corporate presentation as Exhibit 99.1 on May 7, 2026, under Regulation FD.
AVMAPKI FAKZYNJA CO-PACK approved for adult patients with KRAS mutant recurrent Low-Grade Serous Ovarian Cancer.
RAMP 301 Phase 3 trial topline readout expected by mid-2027 for recurrent LGSOC.
Update on RAMP 201 expansion cohort expected in Q2 2026.
VS-7375 KRAS G12D inhibitor early data expected in 1H 2026; first patient in mid-2026 for multiple indications.
Ongoing collaboration with GenFleet Therapeutics for VS-7375 Phase 1/2a study.